p53 immunohistochemistry in bladder cancer-a new approach to an old question

Urologic Oncology: Seminars and Original Investigations

Volumn 28, Issue 4, 2010, Pages 377-388

  Goebell, Peter J ^a   Groshen, Susan G ^b   Schmitz Dräger, Bernd J ^c  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Euromed Clinic   (Germany)

Author keywords

Biomarkers; Bladder cancer; Markers; p53; Prognostic

Indexed keywords

PROTEIN P53; BIOLOGICAL MARKER;

ADULT; ADVANCED CANCER; AGED; BLADDER CANCER; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CORRELATION ANALYSIS; DATA ANALYSIS; EVALUATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MUSCLE METASTASIS; PATIENT CODING; PRIORITY JOURNAL; REVIEW; STANDARDIZATION; STATISTICAL ANALYSIS; SURVIVAL TIME; TUMOR GROWTH; BLADDER TUMOR; CHEMISTRY; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 77953815362     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.03.021     Document Type: Review

References (62)

1. Brown C.J., Lain S., Verma C.S., et al. Awakening guardian angels: Drugging the p53 pathway. Nat Rev Cancer 9 (2009) 862-873
2. Malats N., Kogevinas M., Bustos A., et al. Bladder cancer and p53: An example of what should not be done in biomarker research. Int J Biol Markers 15 (2000) S30
3. Schmitz-Dräger B.J., Goebell P.J., Ebert T., et al. p53 immunohistochemistry as a prognostic marker in bladder cancer: A new toy for urologic scientists?. Eur Urol 38 (2000) 691-700
4. Zlotta A.R., and Schulman C.C. Biological markers in non-muscle-invasive bladder tumors and their prognostic significance. Urol Clin North Am 27 (2000) 179-189
5. Blandino G., Levine A.J., and Oren M. Mutant p53 gain of function: Differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18 (1999) 477-485
6. Weisz L., Oren M., and Rotter V. Transcription regulation by mutant p53. Oncogene 26 (2007) 2202-2211
7. Strano S., Dell'Orso S., Di Agostino S., et al. Mutant p53: An oncogenic transcription factor. Oncogene 26 (2007) 2212-2219
8. Soussi T. p53 alterations in human cancer: More questions than answers. Oncogene 26 (2007) 2145-2156
9. McShane L.M., Aamodt R., Cordon-Cardo C., et al. Reproducibility of p53 immunohistochemistry in bladder tumors. National Cancer Institute, Bladder Tumor Marker Network. Clin Cancer Res 6 (2000) 1854-1864
10. Simon R., and Altman D.G. Statistical aspects of prognostic factor studies in oncology. Br J Cancer 69 (1994) 979-985
11. Hayes D.F. Determination of clinical utility of tumor markers: A tumor marker utility grading system. Recent Results Cancer Res 152 (1998) 71-85
12. Goebell P.J., Groshen S.L., and Schmitz-Dräger B.J. Guidelines for development of diagnostic markers in bladder cancer. World J Urol 26 (2008) 5-11
13. Mallett S., Timmer A., Sauerbrei W., et al. Reporting of prognostic studies of tumor markers: A review of published articles in relation to REMARK guidelines. Br J Cancer 102 (2010) 173-180
14. Shariat S.F., Lotan Y., Vickers A., et al. Statistical consideration for clinical biomarker research in bladder cancer. Urol Oncol 28 (2010) 389-400
15. Schmitz-Dräger B.J., Goebell P.J., and Heydthausen M. The International Study Initiative on Bladder Cancer (ISBC). p53 Immunohistochemistry in bladder cancer: Combined analysis-a way to go?. Urol Oncol 5 (2000) 204-215
16. Shi S.R., Cote R.J., and Taylor C.R. Antigen retrieval immunohistochemistry: Past, present, and future. J Histochem Cytochem 45 (1997) 327-343
17. Goebell P.J., Schmitz-Dräger B.J., Heydthausen M., et al. A critical look at antigen retrieval and choice of antibodies for p53 immunohistochemistry-technical aspects in the ISBC combined analysis. J Urol 167 (2002) 453
18. Keegan P.E., Matthews J.N., Lunec J., et al. Statistical problems with 'optimal' thresholds in studies of new prognostic factors in urology. BJU Int 85 (2000) 392-397
19. Furihata M., Inoue K., Ohtsuki Y., et al. High-risk human papillomavirus infections and overexpression of p53 protein as prognostic indicators in transitional cell carcinoma of the urinary bladder. Cancer Res 53 (1993) 4823-4827
20. Lipponen P.K. Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int J Cancer 53 (1993) 365-370
21. Thomas D.J., Robinson M.C., Charlton R., et al. p53 Expression, ploidy, and progression in pT1 transitional cell carcinoma of the bladder. Br J Urol 73 (1994) 533-537
22. Gardiner R.A., Walsh M.D., Allen V., et al. Immunohistological expression of p53 in primary pT1 transitional cell bladder cancer in relation to tumor progression. Br J Urol 73 (1994) 526-532
23. Hudson M.A., Nadler R.B., Swanson P.E., et al. p53 Protein accumulation in superficial bladder cancer: A predictor of tumor progression which is not affected by intravesical BCG therapy. J Urol 153 (1995) 531
24. Jahnson S., Risberg B., Karlsson M.G., et al. p53 and Rb immunostaining in locally advanced bladder cancer: Relation to prognostic variables and predictive value for the local response to radical radiotheraypy. Eur Urol 28 (1995) 135-142
25. Nakopoulou L., Constantinides C., Papandropoulos J., et al. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: Comparison with DNA ploidy. Urology 46 (1995) 334-340
26. Nakopoulou L., Vourlakou C., Zervas A., et al. The prevalence of bcl-2, p53 and Ki-67 immunoreactivity in transitional cell carcinomas and their clinicopathologic correlates. Hum Pathol 29 (1998) 146-154
27. Tetu B., Fradet Y., Allard P., et al. Prevalence and clinical significance of Her-2/neu, p53 and Rb expression in primary superficial bladder cancer. J Urol 155 (1996) 1784-1788
28. Underwood M.A., Reeves J., Smith G., et al. Overexpression of p53 protein and its significance for recurrent progressive bladder tumors. Br J Urol 77 (1996) 659-666
29. Wu C.S., Pollack A., Czerniak B., et al. Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy. Urology 47 (1996) 305-310
30. Burkhard F.C., Markwalder R., Thalmann G.N., et al. Immunohistochemical determination of p53 overexpression: An easy and readily available method to identify progression in superficial bladder cancer?. Urol Res 25 Suppl. (1997) 31-35
31. Casetta G., Gontero P., Russo R., et al. p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder. Eur Urol 32 (1997) 229-236
32. Popov Z., Hoznek A., Colombel M., et al. Evaluations de la surexpression de la proteine p53 dans le cancer de la vessie: Valeur prognostique. Chirurgie 121 (1996) 461-469
33. Popov Z., Hoznek A., Colombel M., et al. The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder. Cancer 80 (1997) 1472-1481
34. Schmitz-Dräger B.J., Kushima M., and Goebell P. p53 and mdm2 in the development and progression of bladder cancer. Eur Urol 32 (1997) 487-493
35. Abdel-Fattah R., Challen C., Griffiths T.R., et al. Alterations of Tp53 in microdissected transitional cell carcinoma of the human urinary bladder: High frequency of Tp53 accumulation in the absence of detected mutations is associated with poor prognosis. Br J Cancer 77 (1998) 2230-2238
36. Grossman H.B., Liebert M., Antelo M., et al. p53 and Rb expression predict progression in T1 bladder cancer. Clin Cancer Res 4 (1998) 829-834
37. Kakehi Y., Ozdemir E., Habuchi T., et al. Absence of p53 overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas. Jpn J Cancer 89 (1998) 214-220
38. Zlotta A., Noel J.C., Fayt I., et al. Correlation and prognostic significance of p53, p21, and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy. J Urol 161 (1999) 792-798
39. Moch H., Sauter G., Mihatsch M.J., et al. p53 but not erB-2 expression is associated with rapid tumor proliferation in urinary bladder cancer. Hum Pathol 25 (1994) 1346-1351
40. Moch H., Sauter G., Moore D., et al. p53 and erbB-2 protein overexpression are associated with early invasion and metastasis in bladder cancer. Virchows Arch A Pathol Anat Histopathol 423 (1993) 329-334
41. Qureshi K.N., Griffith T.R., Robinson M.C., et al. Tp53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer. Clin Cancer Res 5 (1999) 3500-3507
42. Vet J.A., Bringuier P.P., Schaafsma H.E., et al. Comparison of p53 protein overexpression with p53 mutation in bladder cancer: Clinical and biologic aspects. Lab Invest 73 (1995) 837-843
43. Barbareschi M., Girlando S., Fellin G., et al. Expression of mdm-2 and p53 protein in transitional cell carcinoma. Urol Res 22 (1995) 349-352
44. Leissner J., Gerber M., Fischer U., et al. Predictive value of p53 accumulation in patients with locally advanced bladder cancer. J Urol 155 (1996) 615A
45. Liukkonen T., Rajala P., Raitanen M., et al., Finbladder Group. Prognostic value of MIB-1 Score, p53, EGFr, mitotic index, and papillary status in primary superficial (stage pTa/T1) bladder cancer: A prospective comparative study. Eur Urol 36 (1999) 393-400
46. Bassi P., Spinadin R., Carando R., et al. Dissecting stage T1 bladder cancers by p53. Eur Urol 34 (1998) 297
47. Hermanek P., and Sobin L.H. TNM Classification of Malignant Tumors. 4th ed. (1992), Springer, Berlin, Heidelberg, New York
48. Mostofi F.K. Histological Typing of Urinary Bladder Tumors (1973), Offset Publication 10, WHO, Geneva
49. Spruck III C.H., Ohneseit P.F., Gonzalez-Zulueta M., et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 54 (1994) 784-788
50. Wu X.R. Urothelial tumorigenesis: A tale of divergent pathways. Nat Rev Cancer 5 (2005) 713-725
51. Knowles M.A. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?. Carcinogenesis 27 (2006) 361-373
52. Knowles M.A. Bladder cancer subtypes defined by genomic alterations. Scand J Urol Nephrol 42 (2008) 116-130 4
53. Kulkarni G.S., Hakenberg O.W., Gschwend J.E., et al. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol 57 (2010) 60-70
54. Fritsche H.M., Burger M., Svatek R.S., et al. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: Results from an international cohort. Eur Urol 57 (2010) 300-309
55. Soloway M.S., Lee C.T., Steinberg G.D., et al. Difficult decisions in urologic oncology: Management of high-grade T1 transitional cell carcinoma of the bladder. Urol Oncol 25 (2007) 338-340
56. Witjes J.A. Management of the first recurrence of T1G3 bladder cancer: Does intravesical chemotherapy deserve a chance?. Urol Oncol 27 (2009) 322-324
57. Kulkarni G.S., Alibhai S.M., Finelli A., et al. Cost-effectiveness analysis of immediate radical cystectomy versus intravesical bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer. Cancer 115 (2009) 5450-5459
58. Herr H.W. High-risk, high-grade (T1G3) bladder cancer: Models vs. reality. Cancer 115 (2009) 5366-5367
59. Queipo-Zaragoza J.A., Ruiz-Cerda J.L., Vera-Donoso C.D., et al. Prognostic value of p53, Ki-67, microstaging, and microvessel density in pT1G3 bladder tumors: Creation of risk groups for progression. Scand J Urol Nephrol 41 (2007) 283-289
60. Serretta V, Morgia G, Altieri V, et al. Members of Gruppo Studi Tumori Urologici (GSTU) Foundation (2010). A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-invasive bladder cancer. BJU Int.
61. McShane L.M., Altman D.G., and Sauerbrei W. Identification of clinically useful cancer prognostic factors: What are we missing?. J Natl Cancer Inst 97 (2005) 1023-1025
62. Sauerbrei W. Prognostic factors. Confusion caused by bad quality design, analysis, and reporting of many studies. Adv Otorhinolaryngol 62 (2005) 184-200